2017;10:143 53. S4.3-49. McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 2015;66:1643 53. S4.3-50. Pursnani A, Massaro JM, D Agostino RB Sr, et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA. 2015;314:134 41. S4.3-51. Qureshi WT, Rana JS, Yeboah J, et al. Risk stratification for primary prevention of coronary artery disease: roles of C-reactive protein and coronary artery calcium. Curr Cardiol Rep. 2015;17:110. S4.3-52. Shah RV, Spahillari A, Mwasongwe S, et al. Subclinical atherosclero- sis, statin eligibility, and outcomes in African American individuals: the Jackson Heart Study. JAMA Cardiol. 2017;2:644 52. S4.3-53. Waheed S, Pollack S, Roth M, et al. Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical out- comes with or without statin therapy: The St Francis Heart Study. Atherosclerosis. 2016;255:193 9. S4.3-54. Yeboah J, Polonsky TS, Young R, et al. Utility of nontraditional risk markers in individuals ineligible for statin therapy according to the 2013 American College of Cardiology/American Heart Association cholesterol guidelines. Circulation. 2015;132:916 22. S4.3-55. Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol. 2016;67:139 47. S4.3-56. Krumholz HM. Treatment of cholesterol in 2017. JAMA. 2017;318:417 8. S4.3-57. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discus- sion for atherosclerotic cardiovascular disease prevention: impor- tance to implementation of the 2013 ACC/AHA guidelines. J Am Coll Cardiol. 2015;65:1361 8. S4.3-58. Cohen R, Budoff M, McClelland RL, et al. 